Quick Answer
PMV Pharmaceuticals, Inc. reported Research And Development Expense of $69.88 million for the year ending 2025.
- PMV Pharmaceuticals, Inc. showed an increase of +19.4% in Research And Development Expense from 2024 to 2025.
- This data is from PMV Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $4.90 million | Q1 2020: $5.96 million | Q2 2020: $5.80 million | Q3 2020: $5.99 million | Q1 2021: $7.50 million | Q2 2021: $7.66 million | Q3 2021: $9.16 million | Q1 2022: $11.84 million | Q2 2022: $11.46 million | Q3 2022: $13.67 million | Q1 2023: $15.07 million | Q2 2023: $13.84 million | Q3 2023: $13.59 million | Q1 2024: $13.19 million | Q2 2024: $14.63 million | Q3 2024: $16.95 million | Q1 2025: $17.44 million | Q2 2025: $18.40 million | Q3 2025: $18.21 million.
- Over the full 8 years of available data (2018 to 2025), PMV Pharmaceuticals, Inc.'s Research And Development Expense has grown by 404.4%.
- Historical annual values: Fiscal year 2025: $69.88 million | Fiscal year 2024: $58.53 million | Fiscal year 2023: $55.89 million | Fiscal year 2022: $51.99 million | Fiscal year 2021: $36.49 million | Fiscal year 2020: $23.93 million | Fiscal year 2019: $20.76 million | Fiscal year 2018: $13.85 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: